Seiji Futagami, Hiroshi Yamawaki, Nikki Izumi, Mayumi Shimpuku, Yasuhiro Kodaka, Taiga Wakabayashi, Hiroyuki Nagoya, Tomotaka Shindo, Tetsuro Kawagoe, Katya Gudis, Takashi Itoh, Choitsu Sakamoto
Index: J. Gastroenterol. Hepatol. 28(8) , 1314-20, (2013)
Full Text: HTML
The association between functional dyspepsia (FD) and sleep disorders has yet to be studied in detail. The aim of this study is to evaluate the risk factors associated with sleep disorders and the clinical response to nizatidine therapy for sleep disorders in Rome III-based FD patients.We enrolled 94 FD patients and 52 healthy volunteers. We used Rome III criteria to evaluate upper abdominal symptoms, and the Self-Rating Questionnaire for Depression scores to determine depression status. Sleep disorder was evaluated using Pittsburgh Sleep Quality Index (PSQI) scores, and degree of anxiety by the State-Trait Anxiety Inventory. Gastric motility was evaluated. Thirty-four FD patients were treated with nizatidine (300 mg/day) or placebo for 4 weeks in a crossover trial. The primary end point of this study was to determine whether nizatidine could improve clinical symptoms and sleep disorders in FD patients.The global PSQI score for FD patients was significantly (P < 0.001) higher compared with healthy volunteers. There were significant correlations between global PSQI scores and total Gastrointestinal Symptom Rating Scale and Self-Rating Questionnaire for Depression scores (P < 0.001, P < 0.0001, respectively) in FD patients than in healthy volunteers. We found significant relationships between subjective sleep quality and both Tmax and T1/2 values in FD patients. Nizatidine significantly improved certain clinical symptoms, gastric emptying, and global PSQI score compared with placebo treatment.Sleep disorders in FD patients correlated significantly with both clinical symptoms of dyspepsia and depression compared with healthy volunteers. Nizatidine significantly improved gastroesophageal reflux symptoms, gastric emptying, and sleep disorders in FD patients.© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Nizatidine
CAS:76963-41-2 |
C12H21N5O2S2 |
[Nizatidine].
1989-01-01 [Medicina (Firenze.) 9(1) , 93-6, (1989)] |
Nizatidine improves clinical symptoms and gastric emptying i...
2012-01-01 [Digestion 86(2) , 114-21, (2012)] |
Onset of relief of symptoms of gastroesophageal reflux disea...
2010-04-01 [Clin. Ther. 32(4) , 678-90, (2010)] |
Weight gain management in patients with schizophrenia during...
2006-12-01 [Rev. Bras. Psiquiatr. 28(4) , 270-6, (2006)] |
Predictors and correlates for weight changes in patients co-...
2009-01-01 [BMC Psychiatry 9 , 12, (2009)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved